… erlotinib and afatinib in SCC of the lung. The authors explore the rationale of targeting EGFR
in SCC and the pharmacological properties of erlotinib … 8 trial, which compared erlotinib and …

… erlotinib loaded CSLPHNPs compared to erlotinib solution in A549 cells. Therefore, CSLPHNPs
could be a potential delivery system for erlotinib … erlotinib loaded CSLPHNPs (erlotinib …

… In this study we examined the ability to detect EGFR T790M from plasma DNA from
NSCLC patients that had clinically developed acquired resistance to gefitinib or erlotinib. We …

… Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG)
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …

… the synergistic effect between erlotinib and MAP kinase kinase (MEK) inhibitors in pancreatic
cancer cells and animal models. We show that the combination of erlotinib, an epidermal …

… Although a direct comparison of erlotinib efficacy with that of docetaxel and pemetrexed
will be possible only when data are available from comparative trials, the efficacy of erlotinib …

… We investigated the clinical outcomes of afatinib, erlotinib, and gefitinib according to EGFR
… is uncertain, as comparative studies have been scarce. The present study demonstrated that …

… cells and shows a synergy with erlotinib. Specifically, the cotreatment of sertraline and …
In this study, we demonstrated that sertraline enhanced the therapeutic efficacy of erlotinib in …

… study, we created an EGFR Mutant Structural Database, containing over one hundred EGFR
mutants and their binding free energies with reversible TKIs gefitinib and erlotinib. … erlotinib. …

… After converting the currencies used in the studies to I$, using the CPI and PPP, we found
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …